Latest News
Spero Therapeutics, Inc.
- Spero Therapeutics, Inc. Estimates – NASDAQ:SPRO
- Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
- Spero Therapeutics at Chardan conference: cash-rich bet on SP001
- Spero Therapeutics schedules October 20 chat as target for Spero Therapeutics stock reaches USD 6.00
- Spero Therapeutics CEO to speak at Chardan Heal...
- Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
- Spero's CEO will join a New York fireside chat; a replay will be available for about 90 days.
- Spero Therapeutics grants 556,000 awards to new hires for Spero Therapeutics stock
- Spero Therapeutics (SPRO) Slips 1.68% to $1.17, Holding Above $1.11 Support - Revenue Weighted
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Spero hires get stock awards, but vesting starts after a year
- Discover Spero Therapeutics Alongside Two Promising Penny Stocks
Headlines from the last 30 days, linking to the original publishers. See all market news →